natgillin/translations-raw huggingface dataset:
In the registry study of patients with PNH who had never had a blood transfusion, patients treated with Soliris had clinically meaningful reductions in levels of lactate dehydrogenase (LDH) after 6 months of treatment, indicating reduced breakdown of red blood cells.
V registrski študiji bolnikov s paroksizmalno nočno hemoglobinurijo, ki niso nikoli prejeli transfuzije krvi, je pri bolnikih, ki so bili zdravljeni z zdravilom Soliris, po šestih mesecih zdravljenja prišlo do klinično pomembnega znižanja ravni encima laktatna dehidrogenaza, kar kaže na zmanjšanje razgradnje rdečih krvnih celic.
In the relapsed/refractory study, the median progression-free survival (primary endpoint) was 30.6 months in the R-FC group and 20.6 months in the FC group (p=0.0002, log--rank test).
V študiji pri bolnikih, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje, je bila mediana preživetja brez napredovanja bolezni (primarna končna točka) 30,6 meseca v skupini R- FC in 20,6 meseca v skupini FC (p = 0,0002, test log rank).
In the relapsed/refractory study, the median progression-free survival (primary endpoint) was 30.6 months in the R-FC group and 20.6 months in the FC group (p=0.0002, log-rank test).
V študiji pri bolnikih, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje, je bila mediana preživetja brez napredovanja bolezni (primarna končna točka) 30,6 meseca v skupini R- FC in 20,6 meseca v skupini FC (p = 0,0002, test log rank).
In the renal cell carcinoma study, patients who took Afinitor lived for an average of 4.9 months without the disease getting worse, compared with 1.9 months for the patients who took placebo.
V študiji raka ledvičnih celic pa so bolniki, ki so prejemali zdravilo Afinitor, v povprečju 4,9 meseca živeli brez poslabšanja bolezni v primerjavi z 1,9 meseca pri bolnikih, ki so jemali placebo.
In the reproduction studies, vinflunine appeared to be embryolethal and teratogenic in rabbits and teratogenic in rats.
Pri podganah teratogenega učinka niso mogli izključiti pri odmerkih nad 0,45 mg/kg (2,7 mg/m²).
In the retreatment study AUX-CC-862, 150 anti-AUX-I antibody positive samples and 149 anti-AUX- II antibody positive samples were assessed for potential cross-reactivity with human MMPs-1, -2, -3, - 8, and -13.
V študiji ponovnega zdravljenja AUX-CC-862 so ocenili 150 vzorcev, pozitivnih za protitelesa proti AUX-I, in 149 vzorcev, pozitivnih za protitelesa proti AUX-II, glede morebitne navzkrižne reaktivnosti s človeškimi MMP-1, -2, -3, -8 in -13.
In the Rhesus monkey, whole body radiography following administration of radiolabelled tasonermin indicated no specific distribution pattern.
Pri opici Rhesus radiografija vsega telesa po dajanju radioaktivno označenega tasonermina ni pokazala specifičnega vzorca porazdelitve.
In the Rienso and oral iron groups, 42% and 44% of patients, respectively, were receiving erythropoiesis stimulating agents (ESAs) at Baseline.
V skupini z zdravilom Rienso je eritropoezo stimulirajoča zdravila (ESAs – erythropoiesis stimulating agents) ob izhodišču prejemalo 42 % in v skupini s peroralnim železom 44 % bolnikov.
In the ropinirole group, patients were titrated to their optimal dose up to a maximum of 24 mg/day over 13 weeks.
V skupini, ki je prejemala ropinirol, so bolnikom 13 tednov postopno povečevali odmerek do optimalnega odmerka, do največ 24 mg/dan.
In the sALCL study, 86% of patients (50 out of 58) responded partially or completely to treatment and this response was complete for 59% of them (34 out of 58).
V študiji z bolniki s sistemskim anaplastičnim limfomom velikih celic se je 86 % (50 od 58) bolnikov deloma ali popolnoma odzvalo na zdravljenje, pri 59 % (34 od 58) teh bolnikov pa je bil odziv popoln.
In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported.
V istih kliničnih preskušanjih so poročali o cerebrovaskularnih neželenih dogodkih (cerebrovascular adverse events CVAE, npr. o možganski kapi, tranzitorni ishemični ataki), vključno s smrtnimi izidi.
In the same drug-drug interaction study assessing the effect of dexamethasone, a weaker CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from 7 patients.
V isti študiji medsebojnega delovanja zdravil, ki je na podlagi podatkov 7 bolnikov ocenjevala učinek deksametazona, šibkega induktorja CYP3A4, na farmakokinetiko bortezomiba (danega intravensko), ni bilo pomembnega vpliva na farmakokinetiko bortezomiba.
In the same non-clinical reproduction toxicity study with daclizumab, four out of seven lactating cynomolgus monkeys given a 5 – 10 fold multiple (10 mg/kg) of the normal human dose were found to secrete very low levels of daclizumab (0.17 – 0.28% of maternal serum levels) in breast milk.
V isti predklinični študiji reproduktivne toksičnosti z daclizumabom so štiri od sedmih opic Cynomolgus v laktaciji, ki so prejele 5- do 10-kratni (10 mg/kg) običajni odmerek za ljudi, v mleko izločale zelo majhne vrednosti daclizumaba (0,17 do 0,28 % maternalnih serumskih vrednosti).
In the same study as above, administration of an antacid (aluminium hydroxide/magnesium hydroxide/simethicone) 2 hours before or after a single 400 mg dose of Tasigna also did not alter nilotinib pharmacokinetics.
V isti študiji so opažali, da tudi odmerjanje antacidov (aluminijevega hidroksida/magnezijevega hidroksida/simetikona) 2 uri pred odmerjanjem posameznega odmerka 400 mg zdravila Tasigna ali 2 uri po njem ni vplivalo na farmakokinetiko nilotiniba.
In the same study, a 25% increase in the AUC of theophylline (marker of cytochrome P450 1A2 activity) was observed, demonstrating that Pegasys is an inhibitor of cytochrome P450 1A2 activity.
V isti študiji so opazili tudi 25-% povečanje AUC za teofilin (označevalec aktivnosti citokroma P450 1A2), kar dokazuje, da je zdravilo Pegasys zaviralec aktivnosti citokroma P450 1A2.
In the same study, a statistically significant increase was reported in the incidence of pulmonary embolism (0.7% in the placebo group versus 1.1% in the fenofibrate group; p = 0.022) and a statistically non-significant increase in deep vein thromboses (placebo: 1.0 % [48/4,900 patients] versus fenofibrate 1.4% [67/4,895 patients]; p = 0.074).
V isti študiji so poročali o statistično pomembnem povečanju pogostosti pojavljanja pljučne embolije (0,7 % v skupini, ki je prejemala placebo, v primerjavi z 1,1 % v skupini, ki je prejemala fenofibrat; p = 0,022) in o statistično nepomembnem povečanju pogostosti globoke venske tromboze (1,0 % v skupini, ki je prejemala placebo (48/4900 bolnikov), v primerjavi z 1,4 % v skupini, ki je prejemala fenofibrat (67/4895); p = 0,074).
In the same study, an increased rate of wheezing through 42 days was observed in infants and toddlers 6-23 months of age (5.9% Fluenz versus 3.8% injectable influenza vaccine).
V isti študiji so opazili povišano stopnjo sopenja v obdobju 42 dni pri dojenčkih in malčkih starih od 6 – 23 mesecev (5,9 % cepivo Fluenz v primerjavi s 3,8 % cepivo proti gripi, ki se injicira).
In the same study, an increased rate of wheezing through 42 days was observed in infants and toddlers 6-23 months of age (5.9% T/LAIV versus 3.8% injectable influenza vaccine).
V isti študiji so v obdobju 42 dni opažali večji delež piskajočega dihanja pri dojenčkih in malčkih v starosti od 6 do 23 mesecev (T/LAIV 5,9 % in cepivo proti gripi za injiciranje 3,8 %).
In the same study, in girls aged 9-13 years, the immune response after a 2-dose schedule was numerically lower than after a 3-dose schedule (n=248 at Month 7; n=82 at Month 36).
V isti študiji pri deklicah, starih 9 do 13 let, je bil imunski odziv po 2-odmerni shemi cepljenja številčno manjši kot po 3-odmerni shemi (n = 248 v 7. mesecu; n = 82 v 36. mesecu).
In the same trials with oral aripiprazole, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range:
V istih preskušanjih peroralnega aripiprazola so poročali o cerebrovaskularnih neželenih učinkih (npr. možganski kapi, prehodnem ishemičnem napadu), vključno s smrtnimi primeri (povprečna starost:
In the SAVOR study subgroups over 65 and over 75 years of age, efficacy and safety was consistent with the overall study population.
V preskušanju SAVOR sta se učinkovitost in varnost v podskupinah starejših od 65 in starejših od 75 let skladali s tistima v celotni preiskovani populaciji.
In the SAVOR study subgroups over 65 and over 75 years of age, efficacy and safety was consistent with the overall study population.
V študiji SAVOR sta se učinkovitost in varnost v podskupinah starejših od 65 in starejših od 75 let skladali s tistima v celotni študijski populaciji.
In the second CABG surgery study, four pre-specified event categories were evaluated (cardiovascular/thromboembolic; renal dysfunction/renal failure; upper GI ulcer/bleeding; surgical wound complication).
V drugi študiji v zvezi z operativnim posegom CABG so ocenjevali štiri vnaprej določene kategorije dogodkov (kardiovaskularni/trombembolični, slabo delovanje/odpoved ledvic, razjeda v zgornjih prebavilih/krvavenje, zapleti v zvezi s kirurško rano).
In the second CIN 3 case observed in a patient infected with HPV 51 at Day 1 (in 2 of 9 specimens); HPV 16 was detected at a Month 51 biopsy (in 1 of 9 specimens) and HPV 56 was detected in 3 of 9 specimens at Month 52 in tissue excised during LEEP.
Pri drugem opaženem primeru CIN 3 pri bolnici z okužbo s HPV 51 na 1. dan (v 2 od 9 vzorcev) je bil v 51. mesecu z biopsijo odkrit HPV 16 (v 1 od 9 vzorcev), v 52. mesecu pa je bil v 3 od 9 vzorcev pri eksciziji tkiva s postopkom LEEP odkrit HPV 56.
In the second clinical study (IMPACT 2), efficacy and safety of infliximab were studied in
V drugem preskušanju (IMPACT 2) so proučevali učinkovitost in varnost infliksimaba pri
In the second double-blind 28- week treatment period the difference in rates between treatment groups represented a 63% (rate ratio 0.37, p<0.001) decrease relative to placebo for omalizumab patients.
V drugem 28-tedenskem obdobju dvojno slepega zdravljenja je razlika v pogostnosti eksacerbacij med skupinama predstavljala 63 % (razmerje pogostnosti 0,37, p<0,001) manjšo pogostnost pri bolnikih z omalizumabom v primerjavi z bolniki, ki so prejemali placebo.
In the second field study, a group of 18-day-old embryonated eggs and a group of one-day-old chicks were vaccinated with Vectormune ND.
V drugi terenski študiji so s cepivom Vectormune ND cepili skupino 18 dni starih jajc z zarodki in skupino en dan starih piščancev.
In the second HL study (in patients with HL at increased risk of coming back), the average length of time patients lived before their disease got worse was around 43 months in those given Adcetris, compared with around 24 months in those given placebo.
V drugi študiji Hodgkinovega limfoma (pri bolnikih s HL, izpostavljenimi povečanemu tveganju za ponoven pojav bolezni) je bil povprečen čas preživetja, preden se je bolezen poslabšala, okoli 43 mesecev, pri tistih, ki so prejemali zdravilo Adcetris, v primerjavi s 24 meseci pri tistih, ki so prejemali placebo.
In the second HL study (in patients with HL at increased risk of progressing or coming back), the main measure of effectiveness was how long patients lived without their disease getting worse.
V drugi študiji Hodgkinovega limfoma (pri bolnikih s HL, izpostavljenih povečanemu tveganju za napredovanje ali ponoven pojav bolezni) je bilo glavno merilo učinkovitosti, kako dolgo so bolniki živeli brez poslabšanja bolezni.
In the second ITP study, 57 patients with ITP (baseline platelet counts ≤ 30×109 / l) aged between 18 and 65 years were treated with Privigen at 1 g/kg bw.
V drugi študiji ITP je 57 bolnikov z ITP (izhodiščno število trombocitov ≤ 30×109/l), starih od 18 do 65 let, prejemalo zdravilo Privigen v odmerku 1 g/kg telesne mase.
In the second ITP study, patients taking Revolade were around eight times more likely than those taking placebo to reach a platelet count of between 50,000 and 400,000 per microlitre during the six months of treatment.
V drugi študiji pri bolnikih z imunsko trombocitopenično purpuro je bila pri bolnikih, ki so jemali zdravilo Revolade, verjetnost, da dosežejo število trombocitov med 50 000 in 400 000 na mikroliter v šestih mesecih zdravljenja, približno osemkrat večja kot pri skupini, ki je jemala placebo.
In the second main study involving 122 patients, Ameluz was compared with placebo used for one or two treatment sessionsActinic keratosis cleared in 66% (53 out of 80) of patients treated with Ameluz, compared with 13% (5 out of 40) of patients treated with placebo.
V drugi študiji, v katero je bilo vključenih 122 bolnikov, so aktinične keratoze tri mesece po zdravljenju izginile pri 66 % bolnikov, zdravljenih z zdravilom Ameluz, v primerjavi s 13 % bolnikov, ki so prejemali placebo.
In the second main study involving 341 patients aged over 12 years, PAS in combination with isoniazid was compared with isoniazid alone.
V drugi glavni študiji, v katero je bilo vključenih 341 bolnikov, starih več kot 12 let, so para- aminosalicilno kislino v kombinaciji z izoniazidom primerjali z izoniazidom v monoterapiji.
In the second main study, the change in pain intensity after ten minutes was between 2.0 and 2.7 points after receiving doses of Instanyl compared with 1.3 after receiving placebo.
V drugi glavni študiji je sprememba v intenzivnosti bolečine po desetih minutah znašala med 2,0 in 2,7 točke po prejemu odmerka zdravila Instanyl, po prejemu placeba pa 1,3 točke.
In the second part of the study including patients with prior anticancer therapy but without risk factors for cardiac toxicity, sunitinib was generally tolerable and clinically manageable at the dose of 15 mg/m2/day on schedule 4/2.
V drugem delu študije, ki je vključevala bolnike, ki so predhodno prejemali zdravila za zdravljenje raka in niso imeli dejavnikov tveganja za kardiotoksičnost, so bolniki sunitinib na splošno dobro prenašali in je bil klinično obvladljiv v odmerku 15 mg/m2/dan pri shemi 4/2.
In the second part, the risk of experiencing a disease flare was reduced by 64% with Ilaris, compared with placebo.
V drugem delu druge študije se je tveganje za zagon bolezni zmanjšalo za 64 % pri uporabi zdravila Ilaris v primerjavi s placebom.
In the second Phase 1 study in breast cancer patients in which patients were injected with 20 micrograms Lymphoseek, the mean elimination rate constant of technetium Tc 99m tilmanocept was 0.299/h and the drug half-life at the injection site was 2.6 h.
V drugi študiji 1. faze pri bolnicah z rakom dojke, ki so jim injicirali 20 mikrogramov zdravila Lymphoseek, je bila konstanta povprečne hitrosti izločanja s tehnecijem Tc99m označenega tilmanocepta 0,299/h, razpolovni čas zdravila na mestu injiciranja pa je bil 2,6 h.
In the second prevention study, blood clots or blood-clot related death occurred in 0.4% (3 out of 681) of patients treated with Pradaxa, compared with 5.6% (37 out of 662) of patients treated with placebo.
V drugi študiji preprečevanja so se krvni strdki oziroma smrt bolnika zaradi krvnih strdkov pojavili pri 0,4 % (3 od 681) bolnikov, zdravljenih z zdravilom Pradaxa, v primerjavi s 5,6 % (37 od 662) bolnikov, zdravljenih s placebom.
In the second study (n=16), the median cerebrospinal fluid concentration was 3 % (range 1 to 61 %) of the corresponding plasma concentration.
V drugi študiji (n=16) je mediana koncentracija v cerebrospinalni tekočini znašala 3 % (v intervalu od 1 do 61 %) odgovarjajoče koncentracije v plazmi.
In the second study in 48 patients with mild to moderate asthma who had previously been shown to have bronchoconstrictive reactions to adenosine monophosphate, the rate of FEV1 reduction > 15% from baseline was the same (4%) following both Rapiscan and placebo dosing.
V drugi študiji z 48 bolniki z blago do zmerno astmo, pri katerih se je že prej pokazala bronhokonstrikcijska reakcija na adenozin monofosfat, je bila stopnja zmanjšanja FEV1 > 15% od izhodišča enaka (4%) po dajanju zdravila Rapiscan in placeba.
In the second study in aHUS, 80% of the patients achieved ‘thrombotic microangiopathy event-free’ status and 90% achieved haematological normalisation.
V drugi študiji te bolezni je bila pri 80 % bolnikov trombotična mikroangiopatija brez neželenih dogodkov, pri 90 % pa je prišlo do hematološke normalizacije.
In the second study in women weighing above 60 kg, the average number of eggs collected from each woman was 13.8 in those treated with Elonva compared with 12.6 in those treated with follitropin beta.
V drugi študiji pri ženskah s telesno maso nad 60 kg so tistim, ki so se zdravile z zdravilom Elonva, v povprečju odvzeli 13,8 jajčec, tistim, ki so se zdravile s folitropinom beta, pa 12,6 jajčec.
In the second study involving 63 children less than 12 years of age, children treated with NovoEight had an average of 5.33 bleedings per year.
V drugi študiji, v katero je bilo vključenih 63 otrok, mlajših od 12 let, so imeli otroci, zdravljeni z zdravilom NovoEight, povprečno 5,33 krvavitve na leto.
In the second study of 34 subjects with different impaired hepatic function compared to normal subjects, there was a 1.6-fold, 3.3-fold and 3.6-fold increase in exposure (i.e.
V drugi študiji pri 34 osebah z različno stopnjo okvare jeter v primerjavi z običajnimi osebami je pri osebah z blago okvaro jeter (razreda A po Child-Pughovi lestvici) prišlo do 1,6-kratnega povečanja izpostavljenosti zdravilu (povečanja AUC0-inf), pri osebah z zmerno okvaro jeter (razreda B po
In the second study survival of Eravac vaccinated rabbits was 93% compared with 50% for rabbits given placebo.
V drugi študiji je bilo preživetje kuncev, cepljenih z zdravilom Eravac, 93-odstotno, v primerjavi s 50-odstotnim pri kuncih, cepljenih s placebom.
In the second study the results were similar with 43% of patients in the Fampyra group responding to treatment compared with 9% in the placebo group.
V drugi študiji so bili rezultati podobni, pri čemer se je na zdravljenje odzvalo 43 % bolnikov, ki so jemali zdravilo Fampyra, v primerjavi z 9 % bolnikov, ki so jemali placebo.
In the second study, 15% (10 out of 65) of patients receiving Signifor 40 mg and 20% (13 out of 65) of patients receiving Signifor 60 mg responded to treatment, compared with none of the 68 patients given octreotide or lanreotide.
V drugi študiji se je 15 % (10 od 65) bolnikov, ki so prejemali zdravilo Signifor (40 mg), in 20 % (13 od 65) bolnikov, ki so prejemali zdravilo Signifor (60 mg), odzvalo na zdravljenje v primerjavi z nobenim od 68 bolnikov, ki so prejemali okreotid ali lanreotid.
In the second study, 30% of the patients adding Rapamune failed treatment (68 out of 277), compared with 48% of those adding placebo (62 out of 130).
V drugi študiji je bilo zdravljenje neuspešno pri 30 % bolnikov (68 od 277), ki so jim dodajali zdravilo Rapamune, in pri 48 % bolnikov (62 od 130), ki so dodajali placebo.
In the second study, 38 out of 69 patients (55%) taking 10 mg Revlimd did not need a blood transfusion for at least 182 days, compared with 4 out of 67 (6%) taking placebo.
V drugi študiji 38 od 69 (55 %) bolnikov, ki so jemali 10 mg zdravila Revlimid, ni potrebovalo transfuzije krvi vsaj 182 dni, v primerjavi s 4 bolniki od 67 (6 %), ki so prejemali placebo.
In the second study, 46 (81%) of the 57 patients had a platelet count above 50 million platelets per millilitre at least once during the study.
V drugi študiji je bila pri 46 (81 %) od 57 bolnikov koncentracija trombocitov vsaj enkrat v času trajanja študije nad 50 milijonov trombocitov na mililiter.
In the second study, 52% of the patients receiving Relistor opened their bowels at least twice within four hours of the first four doses (32 out of 62), compared with 8% of those receiving placebo (6 out of 71).
Pri drugi študiji je 52 % (32 od 62) bolnikov, ki so prejeli zdravilo Relistor, odvedlo blato vsaj dvakrat v štirih urah po prvih štirih odmerkih v primerjavi z 8 % (6 od 71) bolnikov, ki so prejeli placebo.
In the second study, 53% (8 out of 15) of children who received Revestive responded to treatment, while none responded to the standard treatment (0 out of 5).
V drugi študiji se je 53 % otrok, ki so prejemali zdravilo Revestive, odzvalo na zdravljenje, na standardno zdravljenje pa nobeden (0 od 5).
In the second study, 61% of patients given Dexdor maintained the required level of sedation compared with 57% of those receiving midazolam.
V drugi študiji je 61 % bolnikov, ki so prejeli zdravilo Dexdor, ohranilo želeno stopnjo sedacije v primerjavi s 57 % tistih, ki so prejeli midazolam.
In the second study, 62% of women using Senshio reported relief from vaginal dryness after 12 weeks (compared with 53% in the placebo group).
V drugi študiji je o zmanjšanju suhosti nožnice po 12 tednih poročalo 62 % žensk, ki so uporabljale zdravilo Senshio (v primerjavi s 53 % v skupini, ki je prejemala placebo).
In the second study, 77% of patients treated with Vibativ (387 out of 502) were cured after treatment compared with 74% of those treated with vancomycin (376 out of 510).
V drugi študiji je bilo ob koncu terapije ozdravljenih 77 % bolnikov (387 od 502), ki so se zdravili z zdravilom Vibativ, v primerjavi s 74 % (376 od 510) bolnikov, ki so jih zdravili z vankomicinom.
In the second study, 81% of patients receiving Zinforo were cured (235 out of 289) compared with 76% of the patients receiving ceftriaxone (206 out of 273).
V drugi študiji je bilo ozdravljenih 81,3 % (235 od 289)bolnikov, ki so prejemali zdravilo Zinforo, v primerjavi s 75,5 % (206 od 273) bolnikov, ki so prejemali ceftriakson.
In the second study, after 14 weeks, 35% of patients who received Simponi alone (54 out of 153) achieved 20% reductions compared with 18% of patients who received placebo (28 out of 155).
V drugi študiji je po 14 tednih prišlo do 20-odstotnega zmanjšanja simptomov pri 35 % (54 od 153) bolnikov, ki so prejemali zdravilo Simponi samostojno, v primerjavi z 18 % (28 od 155) bolnikov, ki so prejemali placebo.
In the second study, among the 28 adults and adolescents with cancer that had not responded to two or more previous treatments, five (18%) had a complete response to treatment.
V drugi študiji je od 28 odraslih in mladostnikov, ki se niso odzvali na najmanj dve predhodni zdravljenji raka, doseglo popoln odziv na zdravljenje pet bolnikov (18 %).
In the second study, around 59% of previously untreated patients with wild-type RAS who were given Vectibix plus FOLFIRI responded to treatment.
V drugi študiji se je na zdravljenje odzvalo okoli 59 % predhodno nezdravljenih bolnikov z divjim tipom gena RAS, ki so prejemali zdravilo Vectibix skupaj s kemoterapijo FOLFIRI.
In the second study, Eliquis was compared with placebo (a dummy treatment) and its effectiveness was measured by looking at the number of patients who either had problems related to clotting in the veins or who died of any cause during treatment.
V drugi študiji so zdravilo Eliquis primerjali s placebom (zdravilom brez zdravilne učinkovine), njegovo učinkovitost pa so merili na podlagi števila bolnikov, ki so med zdravljenjem bodisi imeli težave, povezane z nastajanjem strdkov v venah, bodisi so umrli zaradi katerega koli vzroka.
In the second study, Emtriva was as effective as lamivudine: after 48 weeks, around two thirds of the patients had viral loads below 400 copies/ml, and slightly fewer had viral loads below 50 copies/ml.
V drugi študiji je bilo zdravilo Emtriva enako učinkovito kot lamivudin: po 48 tednih je bila pri dveh tretjinah bolnikov virusna obremenitev pod 400 kopij/ml, pri nekoliko manjšem številu pa je bila virusna obremenitev pod 50 kopij/ml.
In the second study, in 58% of patients Benlysta 10 mg/kg was effective compared with 44% of patients who were given placebo.
V drugi študiji je bilo zdravilo Benlysta učinkovito pri 58 % bolnikov, ki so prejemali odmerek 10 mg/kg, v primerjavi s 44 % bolnikov, ki so prejemali placebo.